Atossa Therapeutics
ATOS
52 hedge funds and large institutions have $20.2M invested in Atossa Therapeutics in 2023 Q2 according to their latest regulatory filings, with 11 funds opening new positions, 10 increasing their positions, 14 reducing their positions, and 3 closing their positions.
1,419% more call options, than puts
Call options by funds: $1.38M | Put options by funds: $91K
267% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 3
70% more capital invested
Capital invested by funds: $11.9M → $20.2M (+$8.3M)
16% more funds holding
Funds holding: 45 → 52 (+7)
0.02% less ownership
Funds ownership: 0.86% → 0.84% (-0.02%)
29% less repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$245K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$216K |
| 3 |
Renaissance Technologies
New York
|
+$112K |
| 4 |
VF
Virtu Financial
New York
|
+$70.2K |
| 5 |
Jane Street
New York
|
+$45.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
D.E. Shaw & Co
New York
|
-$491K |
| 2 |
BlackRock
New York
|
-$247K |
| 3 |
Millennium Management
New York
|
-$119K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$79.5K |
| 5 |
SM
Sabby Management
Miami Beach,
Florida
|
-$47.6K |
ATOS Hedge Fund Activity: Q2 2023 in Review
52 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Atossa Therapeutics (ATOS) for Q2 2023, worth a combined $20.2M — up 70% from $11.9M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new ATOS positions and 3 closed out — a net gain of 8 holders — while 10 added to existing stakes and 14 trimmed.
The largest buyer was GSA Capital Partners, opening a new position worth an estimated $245K. The largest seller was D.E. Shaw & Co, cutting an estimated $491K.
- 52 institutional investors held Atossa Therapeutics (ATOS) as of Q2 2023, up from 45 in Q1 2023.
- Funds reported $20.2M of Atossa Therapeutics stock for Q2 2023, up 70% quarter-over-quarter.
- 11 funds opened new Atossa Therapeutics positions in Q2 2023 and 3 closed out, a net change of +8 holders.
- The largest Atossa Therapeutics buyer in Q2 2023 was GSA Capital Partners, an estimated $245K added.
- The largest Atossa Therapeutics seller in Q2 2023 was D.E. Shaw & Co, an estimated $491K sold.
Based on aggregated 13F filings for Q2 2023.